Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06EXA
|
|||
| Former ID |
DNC005337
|
|||
| Drug Name |
SALVINORIN A
|
|||
| Synonyms |
Salvinorin A; Salvinorin; Divinorin A; 83729-01-5; UNII-T56W91NG6J; CHEMBL445332; T56W91NG6J; CHEBI:67900; 2H-Naphtho(2,1-c)pyran-7-carboxylic acid, 9-(acetyloxy)-2-(3-furanyl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-, methyl ester, (2S-(2alpha,4aalpha,6abeta,7beta,9beta,10aalpha,10bbeta))-; (2S,4aR,6aR,7R,9S,10aS,10bR)-9-(acetyloxy)-2-(3-furanyl)dodechydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho[2,1-c]pyran-7-carboxylic acid methyl ester; (-)-Salvinorin A; herbal ecstasy; Mexican mint; salvinorin-A; Salvonorin A; Diviner's S
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cerebral vasospasm [ICD-11: BA85.Z; ICD-9: 443.9] | Phase 1 | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H28O8
|
|||
| Canonical SMILES |
CC(=O)OC1CC(C2(CCC3C(=O)OC(CC3(C2C1=O)C)C4=COC=C4)C)C(=O)OC
|
|||
| InChI |
1S/C23H28O8/c1-12(24)30-16-9-15(20(26)28-4)22(2)7-5-14-21(27)31-17(13-6-8-29-11-13)10-23(14,3)19(22)18(16)25/h6,8,11,14-17,19H,5,7,9-10H2,1-4H3/t14-,15-,16-,17-,19-,22-,23-/m0/s1
|
|||
| InChIKey |
OBSYBRPAKCASQB-AGQYDFLVSA-N
|
|||
| CAS Number |
CAS 83729-01-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
841714, 10242083, 16381046, 24899776, 29307586, 47437902, 50067596, 50111292, 57342629, 78263362, 103457931, 104045748, 104368418, 121501581, 134221828, 134342542, 135085570, 135652714, 137248535, 143385099, 160711073, 162223660, 163311939, 170485795, 175611615, 177748824, 198941395, 224003872, 226424572, 241146906, 246472304
|
|||
| ChEBI ID |
CHEBI:67900
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Opioid receptor delta (OPRD1) | Target Info | Inhibitor | [3] |
| Opioid receptor kappa (OPRK1) | Target Info | Inhibitor | [4] | |
| Opioid receptor mu (MOP) | Target Info | Inhibitor | [3] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Estrogen signaling pathway | ||||
| Morphine addiction | ||||
| cGMP-PKG signaling pathway | ||||
| Sphingolipid signaling pathway | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Enkephalin release | ||||
| Opioid proenkephalin pathway | ||||
| Opioid proopiomelanocortin pathway | ||||
| Opioid prodynorphin pathway | ||||
| Pathway Interaction Database | IL4-mediated signaling events | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | TCR Signaling Pathway | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | ||||
| Opioid Signalling | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem. 2008 Apr 24;51(8):2421-31. | |||
| REF 4 | Toward a structure-based model of salvinorin A recognition of the kappa-opioid receptor. J Med Chem. 2008 Mar 27;51(6):1824-30. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.